MEDIPOST Obtains Patent for its ‘CARTISTEM’ Production Technology’ in Six European Countries2017/12/06STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Core Alzheimer’s Disease Treatment Technology in Six European Countries2017/10/25STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Commercializing High-efficiency Technology to Culture Stem Cell2017/09/13STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its Stem Cell-based Alzheimer’s Disease Treatment Composition2017/06/28STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for its High-Efficient Technology for Culturing Stem Cells2017/06/14STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells2017/05/17STEM CELL THERAPEUTIC
Chinese Securities Company Praises MEDIPOST as a “Company with Most Profitable Stem Cell Drug”2017/04/26STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Next-Generation Stem Cell Culturing Technology2017/01/10STEM CELL THERAPEUTIC
MEDIPOST Signs MOU with Canadian Public-Private Consortium Funded by the Government of Canada2016/12/01STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in China for Its Brain Disease Treatment Technology that Uses Stem Cells2016/11/30STEM CELL THERAPEUTIC
